Year All20242023202220212020 May 20, 2024 Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024 Read More May 13, 2024 Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates Read More May 13, 2024 Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) Read More May 08, 2024 Fractyl Health to Present at BofA Securities 2024 Health Care Conference Read More May 07, 2024 Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024 Read More Apr 30, 2024 Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting Read More Apr 02, 2024 Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes Read More Apr 01, 2024 Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Read More
May 20, 2024 Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
May 13, 2024 Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024 Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
May 07, 2024 Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
Apr 30, 2024 Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
Apr 02, 2024 Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
Apr 01, 2024 Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update